Publications

Find out about the seasonal influenza vaccines available for the 2025 southern hemisphere season.

Clarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).

Detailed statistical information on Therapeutic Goods Administration performance in pre- and post-market activities.

This report provides information about our regulatory performance for the 2023-24 financial year.

This report provides an overview of pharmacovigilance inspection deficiencies in 2022, including a comparison to results from previous reporting periods.

The findings will inform the need for any risk management actions to ensure public safety.

This plan outlines our compliance and education priorities for 2024-2025.

Read our 2024 stakeholder survey report, which aims to improve the way we work with our stakeholders.

We commissioned the Health Design Lab to conduct market research to better understand the individual consumer, pharmacist and prescriber experiences of shortages and discontinuations.

Read our business plan 2024-25 to find out about our strategic priorities and activities.